Immix Biopharma (Immix Biopharma (IMMX)) had a bit of a mixed day Thursday. On one hand, the company announced some seriously impressive clinical trial results—a 95% complete response rate in patients with a tough-to-treat disease. On the other hand, it also announced a $150 million stock offering, which tends to make investors nervous. The result? Shares dropped about 6%.

Let's start with the good news. Immix is developing a cell therapy called NXC-201 for AL amyloidosis, a disease where abnormal proteins build up in organs like the heart and kidneys, potentially leading to organ failure. In its latest trial update, the company said that 19 out of the first 20 patients treated with NXC-201 achieved a complete response within one year. Even better, none of those patients have relapsed so far. That's a pretty remarkable result, especially considering these patients had already tried a median of four prior treatments. As Gabriel Morris, Immix's President and CFO, put it: "Even in a heavily pretreated population of median 4 prior lines of therapy, we are pleased that NXC-201, as a 5th line of therapy, drives MRD-negativity, converting to durable CRs to-date, indicating that NXC-201 can eliminate the source of toxic light chains that clog up the heart, kidney and liver, causing organ failure and death in relapsed/refractory AL Amyloidosis."

The company plans to start a Phase 3 trial in newly diagnosed patients, with the next clinical update expected in September 2026. By March 2027, they expect to have one-year follow-up data that could support a Biologics License Application (BLA) submission and eventual commercial launch.

Now for the part that spooked the market. Immix priced a public offering of 16.78 million shares at $8.94 each, raising about $150 million. That's a lot of new shares hitting the market, which dilutes existing shareholders. The company says it will use the proceeds to fund NXC-201 development, working capital, and general corporate purposes, and expects the cash to support operations into mid-2028. So while the dilution stings in the short term, it gives Immix a solid runway to keep pushing its promising therapy forward.

From a technical perspective, Immix's stock is currently at $9.28, which is about 4.7% below its 20-day simple moving average of $9.58. The stock has had a phenomenal run over the past year—up 339%—but the MACD indicator is below its signal line, suggesting that momentum is cooling off. Key resistance sits at $11.00, while support is at $8.00. At the time of publication Thursday, shares were trading at $8.39, down 6.15%.

So what's the takeaway? Immix has some genuinely exciting data, and the offering gives it the financial firepower to keep going. But in the short term, the market is focused on the dilution. For investors with a longer horizon, the story might be worth watching—especially when the next data update rolls around in September.